1. Home
  2. TRUP vs TSHA Comparison

TRUP vs TSHA Comparison

Compare TRUP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trupanion Inc.

TRUP

Trupanion Inc.

HOLD

Current Price

$31.33

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$4.49

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRUP
TSHA
Founded
2000
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
TRUP
TSHA
Price
$31.33
$4.49
Analyst Decision
Buy
Strong Buy
Analyst Count
4
9
Target Price
$51.00
$10.56
AVG Volume (30 Days)
377.9K
2.7M
Earning Date
02-12-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
$1,399,759,000.00
$6,310,000.00
Revenue This Year
$14.10
N/A
Revenue Next Year
$9.82
N/A
P/E Ratio
$87.80
N/A
Revenue Growth
12.50
N/A
52 Week Low
$30.85
$1.05
52 Week High
$57.89
$6.02

Technical Indicators

Market Signals
Indicator
TRUP
TSHA
Relative Strength Index (RSI) 30.58 40.79
Support Level $31.19 $4.50
Resistance Level $33.08 $4.89
Average True Range (ATR) 1.36 0.31
MACD -0.25 -0.05
Stochastic Oscillator 9.49 12.06

Price Performance

Historical Comparison
TRUP
TSHA

About TRUP Trupanion Inc.

Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: